SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Vauquelin, G.
Right arrow Articles by Vanderheyden, P. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Vauquelin, G.
Right arrow Articles by Vanderheyden, P. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Distinctions between non-peptide angiotensin II AT1-receptor antagonists

Georges Vauquelin

Department of Molecular and Biochemical Pharmacology, Institute of Molecular Biology and Biotechnology, Free University of Brussels (VUB), B-1640 Sint-Genesius Rode, Belgium, gvauquel{at}vub.ac.be

Frederik LP Fierens

Department of Molecular and Biochemical Pharmacology, Institute of Molecular Biology and Biotechnology, Free University of Brussels (VUB), B-1640 Sint-Genesius Rode, Belgium

Ilse Verheijen

Department of Molecular and Biochemical Pharmacology, Institute of Molecular Biology and Biotechnology, Free University of Brussels (VUB), B-1640 Sint-Genesius Rode, Belgium

Patrick ML Vanderheyden

Department of Molecular and Biochemical Pharmacology, Institute of Molecular Biology and Biotechnology, Free University of Brussels (VUB), B-1640 Sint-Genesius Rode, Belgium

A far-reaching understanding of the molecular action mechanism of AT1-receptor antagonists (AIIAs) was obtained by using CHO cells expressing transfected human AT 1-receptors. In this model, direct [3H]-antagonist binding and inhibition of agonist-induced responses (inositol phosphate accumulation) can be measured under identical experimental conditions. Whereas preincubation with a surmountable AIIA (losartan) causes parallel shifts of the angiotensin II (Ang II) concentration-response curve, insurmountable antagonists also cause partial (i.e., 30% for irbesartan, 50% for valsartan, 70% for EXP3174,) to almost complete (95% for candesartan) reductions of the maximal response. The main conclusions are that all investigated antagonists are competitive with respect to Ang II. They bind to a common or overlapping site on the receptor in a mutually exclusive way. Insurmountable inhibition is related to the slow dissociation rate of the antagonist-receptor complex (t 1/2 of 7 minutes for irbesartan, 17 minutes for valsartan, 30 minutes for EXP3174 and 120 minutes for candesartan). Antagonist-bound AT1-receptors can adopt a fast and a slow reversible state. This is responsible for the partial nature of the insurmountable inhibition. The long-lasting effect of candesartan, the active metabolite of candesartan cilexetil, in vascular smooth muscle contraction studies, as well as in in vivo experiments on rat and in clinical studies, is compatible with its slow dissociation from, and continuous recycling between AT1-receptors. This recycling, or `rebinding' takes place because of the very high affinity of candesartan for the AT1-receptor.

Key Words: CHO cells • angiotensin II • human AT1-receptor • insurmountable • non-peptide antagonists candesartan

References

  • Timmermans PB, Benfield P., Chiu AT, Herblin W., Wong PC Angiotensin II receptors, functional correlates. Am J Hypertens 1992;5:221S-235S.[Medline] [Order article via Infotrieve]
  • Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II Receptors, Angiotensin II Receptor Antagonists. Pharmacological Rev 1993;45:205-51.[Web of Science][Medline] [Order article via Infotrieve]
  • Bumpus FM, Catt KJ, Chiu AT et al. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991;17:720-1.[Free Full Text]
  • Mukojama M., Nakajima M., Horiuchi M., Sasamura H., Pratt RE, Dzau VJ Molecular cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.JBiol Chem 1993;268:24539-42.[Abstract/Free Full Text]
  • Kambayashi Y., Bardhan S., Takahashi K. et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993;268:24543-46.[Abstract/Free Full Text]
  • Vallotton MB The renin-angiotensin system. Trends Pharmacol Sci 1987;8:69-74.[Medline] [Order article via Infotrieve]
  • Zhang JS, Van Meel JCA, Pfaffendorf M., Van Zwieten P. Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein, rabbit aorta; the influence of receptor reserve. J Pharmacol Exp Ther 1993;269:509-14.[Web of Science]
  • Robertson MJ Angiotensin antagonists. In: Leff P (ed). Receptor-based drug design. New York: Marcel Dekker, 1998: 207-23.
  • Liu YJ, Shankley NP, Welsh NJ, Black JW Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible, synoptic action. Br J Pharmacol 1992;106:233-41.[Web of Science][Medline] [Order article via Infotrieve]
  • Criscione L., de Gasparo M., Bühlmayer P., Whitebread S., Ramjoué HP, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1 receptor subtype. Br J Pharmacol 1993;110:761-71.[Web of Science][Medline] [Order article via Infotrieve]
  • Cazaubon C., Gougat J., Bousquet F. et al. Pharmacological characterization of SR 47436, a new non-peptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.[Abstract/Free Full Text]
  • Noda M., Shibouta Y., Inada Y. et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem Pharmacol 1993;46:311-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mochizuki S., Sato T., Furata K. et al. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol 1995;25:22-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Wienen W., Mauz ABM, Van Meel JCA, Entzeroth M. Different types of receptor interaction of peptide, nonpeptide angiotensin II antagonists revealed by receptor binding, functional studies. Mol Pharmacol 1992;41:1081-9.[Abstract]
  • de Chaffoy de Courcelles D., Leysen JE, Roevens P., Van Belle H. The serotonin-S2 receptor: a receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Development Research 1986;8:173-8.[CrossRef][Web of Science]
  • Robertson MJ, Dougall IG, Harper D., Mckechnie KCW, Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci 1994;15:364-69.[CrossRef][Medline] [Order article via Infotrieve]
  • Dickinson KE, Cohen RB, Skwish S. et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br J Pharmacol 1994;113:179-89.[Web of Science][Medline] [Order article via Infotrieve]
  • Wienen W., Hauel N.,Van Meel JCA, Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Olins GM, Chen ST, McMahon EG, Palomo MA, Reitz DB Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629.Mol Pharmacol 1994;47:115-20.[Web of Science]
  • Aiyar N., Baker E., Vickery-Clark L. et al. Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist. Eur J Pharmacol 1995;283:63-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cirillo R., Renzetti AR, Cucchi P. et al. Pharmacology of LR-B/081, a new highly potent, selective, orally active, nonpeptide angiotensin II AT1 receptor antagonist. Br J Pharmacol 1995;114:1117-24.[Web of Science][Medline] [Order article via Infotrieve]
  • De Arriba AF, Gomez-Casajus LA, Cavalcanti F., Almansa C., Garcia-Rafanel J., Forn J. In vitro pharmacological characterization of a new selective angiotensinAT1 receptor antagonist, UR7280. Eur J Pharmacol 1996;318:341-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ojima M., Inada Y., Shibouta Y. et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997;319:137-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Robertson MJ, Barnes JC, Drew GM et al. Pharmacological profile of GR 117289 in vitro: a novel, potent, specific nonpeptide angiotensin AT1 receptor antagonist Br JPharmacol 1992;107:1173-80.[Web of Science][Medline] [Order article via Infotrieve]
  • Panek RL, Lu GH, Overhisser RW, Major TC, Hodges JC, Taylor DG Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharm Exp Ther 1995;273:753-61.[Abstract/Free Full Text]
  • Koh E., Morimoto S.,Tomita J. et al. Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 1994;23:175-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Perlman S., Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW Non-peptide angiotensin agonist. Functional, molecular interaction with the AT1 receptor. J Biol Chem 1995;270:1493-6.[Abstract/Free Full Text]
  • Balmforth AJ, Lee AL,Warburton P., Donnelly D., Ball SG The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III,VII. J Biol Chem 1997; 272:4245-51.[Abstract/Free Full Text]
  • Vanderheyden PML, Fierens FLP, De Backer JP, Frayman N., Vauquelin G. Distinction between surmountable, insurmountable selective AT1-receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1-receptors. Brit J Pharmacol 1999;126:1057-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fierens FLP, Vanderheyden PML, De Backer JP, Vauquelin G. Insurmountable angiotensin II AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 1999;372:199-206.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vanderheyden PML, Fierens FLP, De Backer JP, Vauquelin G. Reversible and syntopic interaction between angiotensin II AT1 receptor antagonists, human AT1 receptors expressed in CHO-K1 cells. Biochem Pharmacol 2000;59:927-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Verheijen I., Fierens FLP, De Backer JP, Vauquelin G., Vanderheyden PML Interaction between the partially insurmountable antagonist valsartan, human recombinant angiotensin II type 1 receptors. Fund Clin Pharmacol 2001;14:577-85.[Web of Science]
  • Pendleton RG, Gessner G., Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal, aorta. J Pharmacol Exp Ther 1989;248:637-43.[Abstract/Free Full Text]
  • Hara M., Kiyama R., Nakajima S. et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol 1995;289:267-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rang HP The kinetic action of acetylcholine antagonists in smooth muscle. Proc R Soc Lond 1965;164:488-510.
  • Rang HP, Dale MM Mechanisms of drug action. In: Rang HP, Dale MM (eds). Pharmacology. London: Churchill Livingstone, 1987; 3-34.
  • Kenakin TP Drug antagonism. In: Kenakin TP (ed). Pharmacological Analysis of Drug-Receptor Interaction. New York: Raven Press, 1987:205-44.
  • Tamura K., Okuhira M., Mikoshiba I., Hashimoto K. In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharmacol Bull 1997;20:850-5.
  • Wong PC, Timmermans PB Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP753. J Pharmacol Exp Ther 1991;258:49-57.[Abstract/Free Full Text]
  • Vauquelin G., Morsing P., Fierens FLP, De Backer JP, Vanderheyden PML. A two-state receptor model for the interaction between angiotensin II AT1 receptors, their non-peptide antagonists. Biochem Pharmacol 2001 (in press).
  • Fierens FLP, Vanderheyden PML, De Backer JP, Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor- transfected Chinese hamster ovary cells. Eur J Pharmacol 1999;367:413-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vanderheyden PML, Fierens FLP, Verheijen I., De Backer JP, Vauquelin G. Binding characteristics of [3H]-irbesartan to human recombinant angiotensin II type 1 receptors. JRAAS 2000;1:159-65.[Medline] [Order article via Infotrieve]
  • De Lean A., Stadel J M., Lefkowitz RJ A ternary complex model explains the agonist-specific properties of the adenylate cyclase- coupled β-adrenergic receptor. J Biol Chem 1980;255:7108-17.[Abstract/Free Full Text]
  • Severne Y., IJzerman A., Nerme V., Zimmerman H., Vauquelin G. Shallow agonist competition binding curves for b-adrenergic receptors: the role for tight agonist binding. Mol Pharmacol 1986;31:69-73.[Web of Science]
  • RenzettiA, Cucci P., Guelfi M., Cirillo R., Salimbeni A.,Giachetti A. Pharmacology of LR-B/057, a novel orally active AT1 receptor antagonist. J Cardiovasc Pharmacol 1995; 25:354-60.[Web of Science][Medline] [Order article via Infotrieve]
  • Monnot C., Bihoreau C., Conchon S., Curnow KM, Corvol P., Clauser E. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding, coupling. Reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem 1996;271:1507-13.[Abstract/Free Full Text]
  • Cvejic S., Devi LA Dimerization of the {delta}-opioid receptor. J Biol Chem 1997;272:26959-64.[Abstract/Free Full Text]
  • Gürdal H., Bond RA, Johnson MD, Friedman E., Onaran HO An efficacy-dependent effect of cardiac overexpression of β2-adrenoceptor on ligand affinity in transgenic mice. Mol Pharmacol 1997;52:187-94.[Abstract/Free Full Text]
  • Anderson KM, Murahashi T., Dorstal DE, Peach MJ Morphological, biochemical analysis of angiotensin II internalisation in cultured rat aortic smooth muscle cells. Am J Physiol 1993;264:C179-C188.[Web of Science][Medline] [Order article via Infotrieve]
  • Hein L., Meinel L., Pratt RE, Dzau VJ, Kobilka BK: Intracellular trafficking of angiotensin II AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997;11:1266-77.[Abstract/Free Full Text]
  • Fierens FLP, Vanderheyden PML et al. Tight binding of the insurmountable antagonist [3H]candesartan to angiotensin II AT1 receptors in intact cells is apparently unrelated to receptor internalisation. Biochem Pharmacol (submitted)
  • Yu SS, Lefkowitz RJ, Hausdorff WP β-Adrenergic receptor sequestration: a potential mechanism of receptor resensitization. J Biol Chem 1993;268:337-41[Abstract/Free Full Text]
  • Duncia JV, Chiu AT, Carini DJ et al. The discovery of potent nonpeptide angiotensin II receptors antagonists: a new class of potent antihypertensives.JMed Chem 1990;33:1312-29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Inoue Y., Nakamura N., Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 1997;15:703-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mirua SI, Feng YH, Huasain A., Karnik SS Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor J Biol Chem 1999;274:7103-10.[Abstract/Free Full Text]
  • Fierens FLP, Vanderheyden PML, Gaborik Z. et al. Lys199 Mutation of the human angiotensin II AT1 receptor differently affects the binding of surmountable, insurmountable nonpeptide antagonists. JRAAS 2001 (in press).
  • Limbird LE Cell Surface Receptors: A Short Course on Theory and Methods, 2nd ed. Boston: KluwerAcad Publ, 1996: 61-122.
  • Morsing P., Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999;33:1406-13.[Abstract/Free Full Text]
  • Lacourcière Y., Asmar R. A comparison of the efficacy, duration of action of candesartan cilexetil, losartan as assessed by clinic, ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999;12:1181-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Delacrétaz E., Nussberger J., Biollaz J., Waeber B., Brunner HR Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14-21.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S24-S31 (2001)
DOI: 10.1177/14703203010020010401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Vauquelin, G.
Right arrow Articles by Vanderheyden, P. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Vauquelin, G.
Right arrow Articles by Vanderheyden, P. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement